Schiller LR. Clinical pharmacology and use of laxatives and lavage solutions. J Clin Gastroenterol 1999;28:11–8.
Noble JA, Grannis FW. Acute esophageal obstruction by a psyllium-based bulk laxative [letter]. Chest 1984;86:800.
Shulman LM, Minagar A, Weiner WJ. Perdiem causing esophageal obstruction in Parkinson's disease. Neurology 1999;52:670–1.
Vergeau B, Nizou C, Ciribilli JM, Grandpierre G. A case of esophageal obstruction after ingestion of a granular laxative [letter]. Endoscopy 1995;27:462.
Perez-Piqueras J, Silva C, Jaqueti J,et al. Endoscopic diagnosis and treatment of an esophageal bezoar resulting from bulk laxative ingestion. Endoscopy 1994;26:710.
William M. The extra pharmacopoeia of Martindale. Reynolds JE, ed. London: Pharmaceutical Press, 1989:1073–1112, 1057–8.
Elliot D, Glover GR. Large bowel perforation due to excessive bran ingestion. Br J Clin Pract 1983;37:32–3.
Souter WA. Bolus obstruction of gut after use of hydrophilic colloid laxatives. BMJ 1965;1:166–8.
Vaswani SK, Hamilton RG, Valentine MD, Adkinson NF. Psyllium laxative-induced anaphylaxis. Allergy 1996;51:266–8.
Busse WW, Schoenwetter WF. Asthma from psyllium in laxative manufacture. Ann Intern Med 1975;83:361–2.
Terho ja Martti Torkko EO. Occupational asthma from psyllium laxatives [in Finnish]. Duodecim 1980;96:1213–6.
Nelson WL. Allergic events among health care workers exposed to psyllium laxatives in the workplace. J Occup Med 1987;29:497–9.
Suhonen R, Kantola I, Bjorksten F. Anaphylactic shock due to ingestion of psyllium laxative. Allergy 1983;38:363–5.
Dutau G, Rittie JL, Rance F, Juchet A, Bremont F. New food allergies. Presse Med 1999;28:1553–9.
Ford MA, Cristea G Jr, Robbins WD, Gentes GR, Harper SJ, Rindone JP. Delayed psyllium allergy in three nurses. Hosp Pharm 1992;27:1061–2.
Bergmann JF, Chassany O, Petit A, Triki R, Caulin C, Segrestaa JM. Correlation between echographic gastric emptying and appetite: influence of psyllium. Gut 1992;33:1042–3.
Rigaud D, Paycha F, Meulemans A, Merrouche M, Mignon M. Effect of psyllium on gastric emptying, hunger feeling and food intake in normal volunteers: a double blind study. Eur J Clin Nutr 1998;52:239–45.
Bandla HP, Davis SH, Hopkins NE. Lipoid pneumonia: a silent complication of mineral oil aspiration. Pediatrics 1999;103:E19.
Schneider L. Pulmonary hazard of the ingestion of mineral oil in the apparently healthy adult: a clinoroentgenologic study. N Engl J Med 1949;240:284–91.
Qureshi T, Melonakos TK. Acute hypermagnesemia after laxative use. Ann Emerg Med 1996;28:552–5.
Gerard SK, Hernandez C, Khayam-Bashi H. Extreme hypermagnesemia caused by an overdose of magnesium-containing cathartics. Ann Emerg Med 1988;17:728–31.
Schelling JR. Fatal hypermagnesemia. Clin Nephrol 2000;53:61–5.
Matsuo H, Nakamura K, Nishida A, Kubo K, Nakagawa R, Sumida Y. A case of hypermagnesemia accompanied by hypercalcemia induced by a magnesium laxative in a hemodialysis patient. Nephron 1995;71:477–8.
Dharmarajan TS, Patel B, Varshneya N. Cathartic-induced life threatening hypermagnesemia in a 90-year-old woman with apparent normal renal function. J Am Geriatr Soc 1999;47:1039–40.
Alison LH, Bulugahapitiya D. Laxative induced magnesium poisoning in a 6-week old infant. BMJ 1990;300:125.
Woodard JA, Shannon M, Lacouture PG, Woolf A. Serum magnesium concentrations after repetitive magnesium cathartic administration. Am J Emerg Med 1990;8:297–300.
Nir-Paz R, Cohen R, Haviv YS. Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure. Ren Fail 1999;21:541–4.
Orias M, Mahnensmith RL, Perazella MA. Extreme hyperphosphatemia and acute renal failure after a phosphorus-containing bowel regimen. Am J Nephrol 1999;19:60–3.
Ehrenpreis ED, Wieland JM, Cabral J, Estevez V, Zaitman D, Secrest K. Symptomatic hypocalcemia, hypomagnesemia, and hyperphosphatemia secondary to Fleet's Phospho-Soda colonoscopy preparation in a patient with a jejunoileal bypass. Dig Dis Sci 1997;42:858–60.
Vukasin P, Weston LA, Beart RW. Oral Fleet Phospho-Soda laxative-induced hyperphosphatemia and hypocalcemic tetany in an adult: report of a case. Dis Colon Rectum 1997;40:497–9.
Escalante CP, Weiser MA, Finkel K. Hyperphosphatemia associated with phosphorus-containing laxatives in a patient with chronic renal insufficiency. South Med J 1997;90:240–2.
Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997;29:103–5.
Filho AJ, Lassman MN. Severe hyperphosphatemia induced by a phosphate-containing oral laxative. Ann Pharmacother 1996;30:141–3.
Fass R, Do S, Hixson LJ. Fatal hyperphosphatemia following Fleet Phospo-Soda [sic] in a patient with colonic ileus. Am J Gastroenterol 1993;88:929–32.
Zipser RD, Bischel MD, Abrams DE. Hypocalcemic tetany due to sodium phosphate ingestion in acute renal failure. Nephron 1975;14:378–81.
Wiberg JJ, Turner GG, Nuttall FQ. Effect of phosphate or magnesium cathartics on serum calcium: observations in normocalcemic patients. Arch Intern Med 1978;138:1114–6.
Schuchmann GD, Barcia PJ. Phosphate absorption from fleet enemas in adults. Curr Surg 1989;46:120–2.
AHFS drug information. Bethesda, MD: American Society of Hospital Pharmacists, 1993:1806–8.
Kaupke C, Sprague T, Gitnick GL. Hypernatremia after the administration of lactulose. Ann Intern Med 1977;86:745–6.
Nelson DC, McGrew WR Jr, Hoyumpa AM Jr. Hypernatremia and lactulose therapy. JAMA 1983;249:1295–8.
Gazda-Smith E, Synhavsky A. Hypernatremia following treatment of theophylline toxicity with activated charcoal and sorbitol. Arch Intern Med 1990;150:689–92.
Allerton JP, Strom JA. Hypernatremia due to repeated doses of charcoal-sorbitol. Am J Kidney Dis 1991;17:581–4.
Aradhye S, Brensilver JM. Sodium phosphate-induced hypernatremia in an elderly patient: a complex pathophysiologic state. Am J Kidney Dis 1991;18:609–11.
Cummings JH. Laxative abuse. Gut 1974;15:758–66.
Fleischer N, Brown H, Graham DY, Delena S. Chronic laxative-induced hyperaldosteronism and hypokalemia simulating Bartter's syndrome. Ann Intern Med 1969;70:791–8.
Wrong O. Aldosterone and electrolyte movements in the colon. BMJ 1968;1:379–80.
Shields R, Mulholland AT, Elmslie R. Action of aldosterone upon the intestinal transport of potassium, sodium, and water. Gut 1966;7:686–96.
Nataf C, Desmazures C, Giraudeaux V, Bernier JJ. Laxative-induced intestinal protein loss in normal subjects. Gastroenterol Clin Biol 1981;5:187–92.
Pahor M, Guralnik JM, Chrischilles EA, Wallace RB. Use of laxative medication in older persons and associations with low serum albumin. J Am Geriatr Soc 1994;42:50–6.
DiPalma JA, DeRidder PH, Orlando RC, Kolts BE, Cleveland MB. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol 2000;95:446–50.
Corazziari E, Badiali D, Bazzocchi G,et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000;46:522–6.
Dunnick JK, Hailey JR. Phenolphthalein exposure causes multiple carcinogenic effects in experimental model systems. Cancer Res 1996;56:4922–6.
Dunnick JK, Hardisty JF, Herbert RA,et al. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (±) mice. Toxicol Pathol 1997;25:533–40.
Gadacz TR, Gaginella TS, Phillips SF. Inhibition of water absorption by ricinoleic acid. Evidence against hormonal mediation of the effect. Am J Dig Dis 1976;21:859–62.
Gaginella TS, Chadwick VS, Debongnie JC, Lewis JC, Phillips SF. Perfusion of rabbit colon with ricinoleic acid: dose-related mucosal injury, fluid secretion, and increased permeability. Gastroenterology 1977;73:95–101.
Stewart JJ, Bass P. Effect of intravenous C-terminal octapeptide of cholecystokinin and intraduodenal ricinoleic acid on contractile activity of the dog intestine. Proc Soc Exp Biol Med 1976;152:213–7.
Wienbeck M, Wallenfels M, Kortenhaus E. Ricinoleic acid and loperamide have opposite motor effects in the small and large intestine of the cat. Z Gastroenterol 1987;25:355–63.
Donowitz M, Binder HJ. Effect of dioctyl sodium sulfosuccinate on colonic fluid and electrolyte movement. Gastroenterology 1975;69:941–50.
Saunders DR, Sillery J, Rachmilewitz D. Effect of dioctyl sodium sulfosuccinate on structure and function of rodent and human intestine. Gastroenterology 1975;69:380–6.
Abramowiecz M. Safety of stool softeners. Med Lett Drugs Ther 1977;19:45–6.
Fox DA, Epstein ML, Bass P. Surfactants selectively ablate enteric neurons of the rat jejunum and gut electrical parameters in the rat jejunum. J Pharmacol Exp Ther 1983;227:538–44.
Morrow DM, Rapaport MJ, Strick RA. Hypersensitivity to aloe. Arch Dermatol 1980;116:1064–5.
Tolman KG, Hammar S, Sannella JJ. Possible hepatotoxicity of Doxidan. Ann Intern Med 1976;84:290–2.
Steer HW, Colin-Jones DG. Melanosis coli: studies of the toxic effects of irritant purgatives. J Pathol 1975;115:199–205.
Walker NI, Bennett RE, Axelsen RA. Melanosis coli. A consequence of anthraquinone-induced apoptosis of colonic epithelial cells. Am J Pathol 1988;131:465–76.
Ghadially FN, Walley VM. Pigments of the gastrointestinal tract: a comparison of light microscopic and electron microscopic findings. Ultrastruct Pathol 1995;19:213–9.
Krbavcic A, Pecar S, Schara M, Muller K, Wiegrebe W. Anthranoid free radicals found in pseudomelanosis coli. Pharmazie 1998;53:336–8.
Benavides SH, Morgante PE, Monserrat AJ, Zarate J, Porta EA. The pigment of melanosis coli: a lectin histochemical study. Gastrointest Endosc 1997;46:131–8.
Hoshi O, Iwanaga T, Fujino MA. Selective uptake of intraluminal dextran sulfate sodium and senna by macrophages in the cecal mucosa of the guinea pig. J Gastroenterol 1996;31:189–98.
Koskela E, Kulju T, Collan Y. Melanosis coli. Prevalence, distribution, and histologic features in 200 consecutive autopsies at Kuopio University Central Hospital. Dis Colon Rectum 1989;32:235–9.
Siegers CP, von Hertzberg-Lottin E, Otte M, Schneider B. Anthranoid laxative abuse—a risk for colorectal cancer? Gut 1993;34:1099–101.
Nusko G, Schneider B, Schneider I, Wittekind C, Hahn EG. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut 2000;46:651–5.
Heiburn N. Roentgen evidence suggesting enterocolitis associated with prolonged cathartic abuse. Radiology 1943;41:486–91.
Muller-Lissner S. What has happened to the cathartic colon? Gut 1996;39:486–8.
Joo JS, Ehrenpreis ED, Gonzalez L,et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. J Clin Gastroenterol 1998;26:283–6.
Campbell WL. Cathartic colon. Reversibility of roentgen changes. Dis Colon Rectum 1983;26:445–8.
Smith B. Effect of irritant purgatives on the myenteric plexus in man and the mouse. Gut 1968;9:139–43.
Krishnamurthy S, Schuffler MD, Rohrmann CA, Pope CE. Severe idiopathic constipation is associated with a distinctive abnormality of the colonic myenteric plexus. Gastroenterology 1985;88:26–34.
Riemann JF, Schmidt H. Ultrastructural changes in the gut autonomic nervous system following laxative abuse and in other conditions. Scand J Gastroenterol Suppl 1982;71:111–24.
Dugan AM. Salmonella typhimurium as a test system for detecting the mutagenic activity of environmental pollutants. Tsitol Genet 1994;28:37–41.
Tikkanen L, Matsushima T, Natori S. Mutagenicity of anthraquinones in the Salmonella preincubation test. Mutat Res 1983;116:297–304.
Brown JP, Brown RJ. Mutagenesis by 9,10-anthraquinone derivatives and related compounds in Salmonella typhimurium. Mutat Res 1976;40:203–24.
Brown JP, Dietrich PS. Mutagenicity of anthraquinone and benzanthrone derivatives in the salmonella/microsome test: activation of anthraquinone glycosides by enzymic extracts of rat cecal bacteria. Mutat Res 1979;66:9–24.
Venturini S, Tamaro M. Mutagenicity of anthraquinone and azo dyes in Ames' Salmonella typhimurium test. Mutat Res 1979;68:307–12.
Krivobok S, Seigle-Murandi F, Steiman R, Marzin DR, Betina V. Mutagenicity of substituted anthraquinones in the Ames/Salmonella microsome system. Mutat Res 1992;279:1–8.
Heidemann A, Volkner W, Mengs U. Genotoxicity of aloeemodin in vitro and in vivo. Mutat Res 1996;367:123–33.
Sandnes D, Johansen T, Teien G, Ulsaker G. Mutagenicity of crude senna and senna glycosides in Salmonella typhimurium. Pharmacol Toxicol 1992;71:165–72.
Muller SO, Eckert I, Lutz WK, Stopper H. Genotoxicity of the laxative drug components emodin, aloe-emodin and danthron in mammalian cells: topoisomerase II mediated? Mutat Res 1996;371:165–73.
Schorkhuber M, Richter M, Dutter A, Sontag G, Marian B. Effect of anthraquinone-laxatives on the proliferation and urokinase secretion of normal, premalignant and malignant colonic epithelial cells. Eur J Cancer 1998;34:1091–8.
Lee H, Tsai SJ. Effect of emodin on cooked-food mutagen activation. Food Chem Toxicol 1991;29:765–70.
al-Dakan AA, al-Tuffail M, Hannan MA. Cassia senna inhibits mutagenic activities of benzo[a]-pyrene, aflatoxin B1, shamma and methyl methanesulfonate. Pharmacol Toxicol 1995;77:288–92.
Toyoda K, Imaida K, Shirai T, Imazawa T, Takahashi M. Relationship between bisacodyl-induced urolithiasis and rat urinary bladder tumorigenesis. J Toxicol Environ Health 1993;39:59–78.
Mori H, Yoshimi N, Iwata H,et al. Carcinogenicity of naturally occurring 1-hydroxyanthraquinone in rats: induction of large bowel, liver and stomach neoplasms. Carcinogenesis 1990;11:799–802.
Mori H, Sugie S, Niwa K, Yoshimi N, Tanaka T, Hirono I. Carcinogenicity of chrysazin in large intestine and liver of mice. Jpn J Cancer Res 1986;77:871–6.
Mori H, Sugie S, Niwa K, Takahashi M, Kawai K. Induction of intestinal tumours in rats by chrysazin. Br J Cancer 1985;52:781–3.
Mereto E, Ghia M, Brambilla G. Evaluation of the potential carcinogenic activity of Senna and Cascara glycosides for the rat colon. Cancer Lett 1996;101:79–83.
Mascolo N, Mereto E, Borrelli F,et al. Does senna extract promote growth of aberrant crypt foci and malignant tumors in rat colon? Dig Dis Sci 1999;44:2226–30.
Lyden-Sokolowski A, Nilsson A, Sjoberg P. Two-year carcinogenicity study with sennosides in the rat: emphasis on gastrointestinal alterations. Pharmacology 1993;47(Suppl 1):209–15.
Kleibeuker JH, Cats A, Zwart N, Mulder NH, Hardonk MJ, de Vries EG. Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst 1995;87:452–3.
Van Gorkom BA, Karrenbeld A, van Der Sluis T, Koudstaal J, de Vries EG, Kleibeuker JH. Influence of a highly purified senna extract on colonic epithelium. Digestion 2000;61:113–20.
Jacobs EJ, White E. Constipation, laxative use, and colon cancer among middle-aged adults. Epidemiology 1998;9:385–91.
Sonnenberg A, Muller AD. Constipation and cathartics as risk factors of colorectal cancer: a meta-analysis. Pharmacology 1993;47(Suppl 1):224–33.
Nusko G, Schneider B, Muller G, Kusche J, Hahn EG. Retrospective study on laxative use and melanosis coli as risk factors for colorectal neoplasma. Pharmacology 1993;47(Suppl 1):234–41.
Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumor sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 1999;14:2892–7.
Kune GA. Laxative use not a risk for colorectal cancer: data from the Melbourne Colorectal Cancer Study. Z Gastroenterol 1993;31:140–3.
Longnecker MP, Sandler DP, Haile RW, Sandler RS. Phenolphthalein-containing laxative use in relation to adenomatous colorectal polyps in three studies. Environ Health Perspect 1997;105:1210–2.
Dukas L, Willet WC, Colditz GA, Fuchs CS, Rosner B, Giovannucci EL. Prospective study of bowel movement, laxative use, and risk of colorectal cancer among women. Am J Epidemiol 2000;151:958–64.